NLTX Insider Trading Activity and SEC Form 4 Filings
NLTX insider trading summary
No open-market insider purchases or sales of Neoleukin Therapeutics, Inc. (NLTX) have been reported on SEC Form 4 in the past 12 months.
Latest NLTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 17, 2023 | Baker Bros. Advisors (GP) LLC | Director | Buy | $5K (7,676 @ $0.69) |
| Aug 17, 2023 | Julian Baker | Director | Buy | $64K (93,091 @ $0.69) |
| Aug 17, 2023 | Felix Baker | Director | Buy | $5K (7,676 @ $0.69) |
| Aug 17, 2023 | Julian Baker | Director | Buy | $5K (7,676 @ $0.69) |
| Aug 17, 2023 | Baker Bros. Advisors LP | Director | Buy | $64K (93,091 @ $0.69) |
| Aug 17, 2023 | Felix Baker | Director | Buy | $64K (93,091 @ $0.69) |
| Aug 17, 2023 | Baker Bros. Advisors LP | Director | Buy | $5K (7,676 @ $0.69) |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director | Buy | $5K (7,676 @ $0.69) |
| Aug 17, 2023 | 667, L.P. | Director | Buy | $5K (7,676 @ $0.69) |
| Aug 17, 2023 | 667, L.P. | Director | Buy | $64K (93,091 @ $0.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.